Photo of Nazia Khan

Nazia Khan is an associate in the Corporate Practice Group in the firm's Washington D.C. office.

On August 29, 2023, less than one year after President Biden’s directive to federal officials, including the U.S. Department of Health and Human Services (“HHS”) and the U.S. Attorney general, to conduct a review of cannabis’ classification under federal law,[1] HHS submitted a letter to the U.S. Drug Enforcement Agency (“DEA”) recommending a change in cannabis’ classification under the federal Controlled Substances Act (“CSA”).Continue Reading Reclassifying Cannabis as a Schedule III Substance – Will the DEA Agree?